These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35643048)

  • 1. Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada.
    Sud A; McGee M; Mintzes B; Herder M
    Int J Drug Policy; 2022 Jul; 105():103749. PubMed ID: 35643048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Suboxone's Market Exclusivity on Cost of Opioid Use Disorder Treatment.
    McGee M; Chiu K; Moineddin R; Sud A
    Appl Health Econ Health Policy; 2023 May; 21(3):501-510. PubMed ID: 36652186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
    Barenie RE; Sinha MS; Kesselheim AS
    Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis.
    Sud A; Strang M; Buchman DZ; Spithoff S; Upshur REG; Webster F; Grundy Q
    BMJ Open; 2022 Jul; 12(7):e059561. PubMed ID: 35820738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Canadian and United States opioid agonist therapy policies.
    Priest KC; Gorfinkel L; Klimas J; Jones AA; Fairbairn N; McCarty D
    Int J Drug Policy; 2019 Dec; 74():257-265. PubMed ID: 30765118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic Drug Policy and Suboxone to Treat Opioid Use Disorder.
    Haffajee RL; Frank RG
    J Law Med Ethics; 2019 Dec; 47(4_suppl):43-53. PubMed ID: 31955697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid Use Disorder: Treatment Outcomes in U.S. Veterans.
    Griffith PS; Brown LM; Lensing SY; Nahata R; Padala PR; Snow L; Milholland K; Mullins M
    J Addict Nurs; 2022 Oct-Dec 01; 33(4):322-325. PubMed ID: 37140420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leveraging black-market street buprenorphine pricing to increase capacity to treat opioid addiction, 2010-2018.
    Hswen Y; Zhang A; Brownstein JS
    Prev Med; 2020 Aug; 137():106105. PubMed ID: 32353575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Micro-induction of Buprenorphine/Naloxone for Opioid Use Disorder in a Critically ill Intubated Patient: A Case Report.
    Hamata B; Griesdale D; Hann J; Rezazadeh-Azar P
    J Addict Med; 2020 Dec; 14(6):514-517. PubMed ID: 32649330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
    Doernberg M; Krawczyk N; Agus D; Fingerhood M
    Subst Abus; 2019; 40(2):148-153. PubMed ID: 31008694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
    Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
    J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
    [No Abstract]   [Full Text] [Related]  

  • 13. Association between buprenorphine/naloxone and high-dose opioid analgesic prescribing in Kentucky, 2012-2017.
    Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Slade E; Bush H
    Drug Alcohol Depend; 2019 Dec; 205():107606. PubMed ID: 31606590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.
    Farrell MacDonald S; Russell C; Beauchamp T; Derkzen D; Fischer B
    Int J Drug Policy; 2022 Feb; 100():103480. PubMed ID: 34656817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medicare coverage of buprenorphine-naloxone film surrounding generic entry.
    Zhang H; Bao Y; Kapadia SN
    Am J Manag Care; 2023 Aug; 29(8):e257-e260. PubMed ID: 37616154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019-2020).
    Dana SR; Nichols SD; McCall KL; Piper BJ
    J Stud Alcohol Drugs; 2024 Jan; 85(1):19-25. PubMed ID: 37650858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.
    Turner L; Kruszewski SP; Alexander GC
    Am J Addict; 2015 Jan; 24(1):24-9. PubMed ID: 25823632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mobile addiction service for community-based overdose prevention.
    Pepin MD; Joseph JK; Chapman BP; McAuliffe C; O'Donnell LK; Marano RL; Carreiro SP; Garcia EJ; Silk H; Babu KM
    Front Public Health; 2023; 11():1154813. PubMed ID: 37538275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Motivations for Nonprescribed Buprenorphine Use Among Rural Appalachian Substance Users.
    McDonald MJ; DeVeaugh-Geiss AM; Chilcoat HD; Havens JR
    J Addict Med; 2023 Jan-Feb 01; 17(1):95-100. PubMed ID: 36044288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of buprenorphine/naloxone prescribing: an analysis of claims data from Massachusetts.
    Paulsen R; Modestino AS; Hasan MM; Noor-E-Alam M; Young LD; Young GJ
    Am J Drug Alcohol Abuse; 2020; 46(2):216-223. PubMed ID: 31825718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.